$DFTX SEC Filings

Filed On	Filing
29 Sep 2026	Form 4: Karlin Daniel, Director Sold 10,853 shares ($397K)
29 Sep 2026	Form 4: Barrow Robert, Director Sold 31,550 shares ($1.15M)
29 Sep 2026	Form 4: Wiley Matthew T., Chief Commercial Officer Sold 3,097 shares ($113K)
29 Sep 2026	Form 4: Sullivan Mark, Chief Legal Officer Sold 14,051 shares ($514K)
29 Sep 2026	Form 4: Roberts Brandi, Chief Financial Officer Sold 3,377 shares ($123K)
25 Sep 2026	144
25 Sep 2026	144
25 Sep 2026	144
25 Sep 2026	144
25 Sep 2026	144
18 Sep 2026	Form 4: Krebs Andreas, Director Received 1,629 shares by exercise or conversion ($57.9K)
18 Sep 2026	Form 4: Vallone Carol A, Director Received 1,086 shares by exercise or conversion ($38.6K)
14 Sep 2026	Form 4: Karlin Daniel, Chief Medical Officer Received 200,000 shares as a grant or award
14 Sep 2026	Form 4: Wiley Matthew T., Chief Commercial Officer Received 125,000 shares as a grant or award
14 Sep 2026	Form 4: Sullivan Mark, Chief Legal Officer Received 125,000 shares as a grant or award
14 Sep 2026	Form 4: Roberts Brandi, Chief Financial Officer Received 125,000 shares as a grant or award
14 Sep 2026	Form 4: Barrow Robert, Director Received 750,000 shares as a grant or award
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou r” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solic...
08 Sep 2026	8-K: Other Events Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
04 Sep 2026	Form 4: Barrow Robert, Director Received 40,000 shares as a grant or award · Sold 19,023 shares ($722K)

Comments